Volha Barysevich/iStock via Getty Images AC Immune ( NASDAQ: ACIU ) stock shot up 20% Thursday after the company reported positive interim data from a Phase 2 study of its drug ACI-7104.056 in the treatment of early Parkinson’s disease. The study, called VacSYn, showed the drug induced high anti-a-synuclein antibody.
